Related Experiment Video

Updated: May 4, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

4.6K

The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects

D B Ojji1, L H Opie2, S Lecour2

  • 11] Cardiology Unit, Department of Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria [2] Faculty of Health Sciences, Department of Medicine, Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa.

Journal of Human Hypertension
|January 10, 2014
PubMed

Insights

Soluble ST2 effectively differentiates hypertensive heart failure (HHF) from hypertension with or without left ventricular hypertrophy (LVH). This biomarker also distinguishes hypertensive LVH from hypertension without LVH, aiding in diagnosis.

Area of Science:

  • Cardiology
  • Biomarkers
  • Hypertension Research

Background:

  • Soluble ST2 (sST2) is a known biomarker for cardiomyocyte stretch and has prognostic value in coronary artery disease.
  • The role of sST2 in hypertension and hypertensive heart failure (HHF) remains under-investigated.
  • Left ventricular remodeling is a key feature in hypertension, influencing cardiac outcomes.

Purpose of the Study:

  • To investigate the effect of left ventricular remodeling on plasma soluble ST2 concentrations in hypertensive patients.
  • To assess the utility of sST2 in differentiating stages of hypertensive heart disease, including HHF and left ventricular hypertrophy (LVH).

Main Methods:

  • A cohort of 210 hypertension (HT) patients was studied, categorized into HT without LVH (n=83), HT with LVH (HTLVH, n=50), and HHF (n=77).
  • Left ventricular hypertrophy was defined using echocardiographic criteria based on left ventricular mass indexed to height.
  • Plasma concentrations of soluble ST2 and NT-pro BNP were measured using electrochemiluminescence immunoassays.

Main Results:

  • Subjects with HHF exhibited significantly higher plasma sST2 levels compared to both HTLVH and HT groups (P < 0.001 and P < 0.0001, respectively).
  • NT-pro BNP levels were elevated in HHF compared to HTLVH (P < 0.0002), but similar between HTLVH and HT (P = 0.68).
  • Plasma sST2 demonstrated a strong correlation with clinical and echocardiographic parameters, as well as with NT-pro BNP (r = 0.41, P < 0.0001).

Conclusions:

  • Plasma sST2 is a valuable biomarker for distinguishing HHF from hypertension with or without LVH.
  • sST2 can also differentiate hypertensive LVH from hypertension without LVH.
  • These findings highlight the potential of sST2 as a diagnostic tool in the spectrum of hypertensive heart disease.

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

9.8K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.3K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
886
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K